Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors

NCT07023731 is registered in ClinicalTrials.gov with Arvinas Inc. as lead sponsor.

NCT NCT07023731
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07023731 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Lead sponsor
Arvinas Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 29, 2025
Completion date
November 30, 2026
Enrollment
76 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid cancer, kras g12d mutation